Drugs / AK131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06166888 | Jan 2024 → Aug 2026 overdue | neoplasm | Akeso | Recruiting | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05076682 | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-12 | Akeso | Results AACR 特辑|康方生物发布PD-1/CD73双抗（AK131）临床前研究结果 akesobio.com ↗
研究显示，AK131可显著抑制肿瘤体积生长，具有强大的抗肿瘤活性. |
| 2022-03-17 | Akeso | Results 康方生物两款全新双抗在内的多项研究成果将在2022 AACR年会发表 akesobio.com ↗
在临床前体内药效学研究中，AK129显示了强大的抗肿瘤活性，小鼠模型中AK129的肿瘤生长抑制率可达99.27% （20mg/kg）、89.48%（4mg/kg）. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-12 | Akeso | AACR 特辑|康方生物发布PD-1/CD73双抗（AK131）临床前研究结果 akesobio.com ↗ |
| 2022-03-17 | Akeso | 康方生物两款全新双抗在内的多项研究成果将在2022 AACR年会发表 akesobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05076682 ↗ |
| Action | Inhibit | “anti-PD-1” NCT06166888 ↗ |
| Route | Intravenous | “i.v.” NCT05076682 ↗ |